Gaucher disease (GD) is a rare condition caused by an inherited, autosomal recessive deficiency of the enzyme P-glucocerebrosidase, resulting in an accumulation of glucocerebroside in the lysosomes of macrophages and monocytes. Three distinct clinical forms are recognized. Type 1 (chronic non-neuropathic or 'adult form') is the most common, and its onset can occur at any age. This form is most frequent among Ashkenazy Jews, although any race can be affected. It is characterized by hepatosplenomegaly, thrombocytopenia and bone lesions, and lung involvement is rare (1 with a clinical picture consisting of a 7-cm hepatomegaly and a 12-cm splenomegaly, pancytopenia and bone lesions, and after observation of characteristic Gaucher disease cells in a bone marrow biopsy and detection of enzyme deficiency in peripheral leukocytes (6% of control value). DNA analysis showed a N370S/D55 genotype. Thrombocytopenia (platelet counts: 21 000 ,u-'), anaemia (haemoglobin: 8.1 g dl ~ ') and haemorrhagic manifestations increased subsequently, and a splenectomy was performed at age 19 years, with a subsequent correction in blood counts.
From 1993 (at the age of 24 years), she began to suffer from progressive exertional dyspnoea and impaired pulmonary function tests, with a reduction of carbon monoxide diffusing capacity (DLCO) ( 1995 with alglucerase (CeredaseO, Genzyme Co., Cambridge, MA) at 2.3 U kg -' in i.v. infusion three times a week (total dose 32 400 U). The patient had no adverse reactions. Eight months later an abdominal ultrasonography showed a 3-cm reduction in her hepatomegaly, her dyspnoea improved and an increase in DLCO was noted (Table 1) . Fifteen months after the onset of treatment, an echocardiography was performed, showing a significant enlargement of the pulmonary artery (37.9 mm) and right cavities, with a pulmonary artery systolic pressure of 74 mmHg and normal left ventricular function. Six months later, a second echocardiography showed no relevant changes. The patient refused right cardiac catheterization. As tolerance and clinical response were good, ERT treatment was continued at a dose of 15 U kg ~ i every 2 weeks.
Discussion
While pulmonary involvement is relatively common in type 2 and type 3 GD, it is infrequent in the adult or type 1 form, with only a few isolated reports in the medical literature (2) . In a series of type 1 GD patients, symptomatic lung involvement was only found in 3.7% (1). However, anatomical descriptions from necropsic studies, including the three distinct GD clinical forms, showed pulmonary involvement in up to one-third of the patients (3), and that 42% of the patients in a large series had a significant decrease in DLCO (4).
Most GD patients present with exertion dyspnoea, but chest radiographs are usually normal and a diffuse interstitial pattern is seen only in 17% (4). Respiratory insufficiency might be due to intrapulmonary artery-vein anastomosis, probably secondary to hepatic involvement, or otherwise to lung parenchymal involvement (2) . Lung involvement has three predominant forms: 1. interstitial infiltration with Gaucher cells; 2. Gaucher cells occluding the pulmonary capillaries; and 3. Gaucher cells filling the alveolar space, producing consolidation (3). Another form of pulmonary involvement in GD is pulmonary hypertension (PHT): a severe complication associated with poor prognosis. Four possible pathophysiological mechanisms might account for the development of PTH in the individual with GD: 1. perivascular infiltration by Gaucher cells with vascular obliteration; 2. plugging of the capillaries with Gaucher cells; 3. occlusion of the vasculature by fat emboli; and 4. the development of PTH in the absence of cellular intiltrationZ with a pathological lesion similar to that seen in primary PHT (5) .
From 1990 onwards, treatment of GD has been by ERT. This treatment may revert symptoms in the majority of the patients and substantially improve their quality of life. Up to 2000 patients world-wide are being treated with alglucerase. Alglucerase is a human placental derivative of P-glucocerebrosidase; designed for increasing enzyme capture by macrophages, which catalyses glucocerebroside hydrolysis (6,7). There has been little experience of ERT in pulmonary disease. Only three cases have been described in the U.S.A. in which a good response was obtained after prolonged therapy (up to 20 months) with i.v. alglucerase (8, 9) . However, all reports agree that this is an important indication for the use of ERT (6,7).
Dawson et ul. (8) described two patients treated with alglucerase who developed PHT which was not present prior to treatment. In their article, they discuss the possible pathogenetic mechanisms for this complication, and cannot exclude an adverse effect of alglucerase. Unfortunately, we did not measure initial pulmonary artery pressure in our patient, so cannot be sure whether PHT existed before the start of ERT. However, a chest radiograph obtained 2 years before the start of treatment showed an existing enlargement of the pulmonary artery, thus it is likely that PHT did exist previously. However, we cannot discard the possibility of an influence of ERT on the development of PHT, as reported in two patients by Harats et al. (10) .
After 18 months of enzyme replacement theapy, a good clinical response has been obtained in our patient, as well as an improvement in functional respiratory parameters, especially in DLCO. Nevertheless, we cannot rule out the possibility that DLCO increase was secondary to the development of PHT, as the latter causes changes in perfusion distribution, with an improvement of perfusion in upper pulmonary areas. Whilst the pathogenic mechanisms of PHT in type 1 GD and the possible role for alglucerase in its development cannot be clarified, we consider close follow-up to be important in all ERT-treated patients, and suggest echocardiography and measurement of pulmonary artery pressure and tricuspid gradient prior to the onset of alglucerase treatment as general practice in all GD patients.
